Notable Price Action: Ocera Therapeutics Inc’s Stock Is Buy After Today’s Significant Increase

Notable Price Action: Ocera Therapeutics Inc's Stock Is Buy After Today's Significant Increase

The stock of Ocera Therapeutics Inc (NASDAQ:OCRX) is a huge mover today! About 86,713 shares traded hands. Ocera Therapeutics Inc (NASDAQ:OCRX) has declined 27.18% since March 29, 2016 and is downtrending. It has underperformed by 30.66% the S&P500.
The move comes after 5 months positive chart setup for the $55.76M company. It was reported on Oct, 31 by Barchart.com. We have $4.43 PT which if reached, will make NASDAQ:OCRX worth $50.18M more.

Analysts await Ocera Therapeutics Inc (NASDAQ:OCRX) to report earnings on November, 2. They expect $-0.36 EPS, down 5.88% or $0.02 from last year’s $-0.34 per share. After $-0.33 actual EPS reported by Ocera Therapeutics Inc for the previous quarter, Wall Street now forecasts 9.09% negative EPS growth.

According to Zacks Investment Research, “Ocera Therapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of proprietary compounds to treat acute and chronic orphan liver diseases. Ocera Therapeutics, Inc., formerly known as Tranzyme, Inc., is based in San Diego, California.”

Insitutional Activity: The institutional sentiment decreased to 0.62 in 2016 Q2. Its down 0.15, from 0.77 in 2016Q1. The ratio fall, as 3 funds sold all Ocera Therapeutics Inc shares owned while 10 reduced positions. 2 funds bought stakes while 6 increased positions. They now own 6.77 million shares or 0.29% less from 6.79 million shares in 2016Q1.
Glenmede Trust Na, a Pennsylvania-based fund reported 11,352 shares. Renaissance Technologies Ltd Company last reported 169,100 shares in the company. Qvt L P holds 0.1% or 932,086 shares in its portfolio. Vanguard Grp Inc Inc last reported 408,835 shares in the company. The Ontario – Canada-based Manufacturers Life Ins The has invested 0% in Ocera Therapeutics Inc (NASDAQ:OCRX). Retail Bank Of New York Mellon Corporation accumulated 34,136 shares or 0% of the stock. Blackrock Invest Mngmt Ltd last reported 2,386 shares in the company. Tower Rech Capital (Trc) has invested 0% of its portfolio in Ocera Therapeutics Inc (NASDAQ:OCRX). The New York-based Ghost Tree Capital Lc has invested 0.02% in Ocera Therapeutics Inc (NASDAQ:OCRX). Morgan Stanley has invested 0% of its portfolio in Ocera Therapeutics Inc (NASDAQ:OCRX). The Illinois-based Northern Trust has invested 0% in Ocera Therapeutics Inc (NASDAQ:OCRX). Vhcp Mngmt Ltd Com last reported 1.57% of its portfolio in the stock. Millennium Mgmt Limited Liability Corp accumulated 516,343 shares or 0% of the stock. Sabby Limited Liability Company last reported 0.04% of its portfolio in the stock. Endurant Management L P has invested 0.07% of its portfolio in Ocera Therapeutics Inc (NASDAQ:OCRX).

Insider Transactions: Since October 13, 2016, the stock had 1 buy, and 0 insider sales for $6,598 net activity. Bukofzer Stan bought $6,598 worth of stock or 2,500 shares.

Another recent and important Ocera Therapeutics Inc (NASDAQ:OCRX) news was published by Globenewswire.com which published an article titled: “Ocera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to …” on October 28, 2016.

OCRX Company Profile

Ocera Therapeutics, Inc., incorporated on January 12, 1998, is a clinical-stage biopharmaceutical company. The Firm is focused on acute and chronic orphan liver diseases. The Firm is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. The Firm relies on third-party manufacturers to produce bulk drug substance and drug products required for commercial use and for its clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment